A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

Serena Williams, the tennis icon, has revealed her postpartum weight loss journey, shedding 31 pounds with the help of GLP-1 ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Sales of the weight loss injection Wegovy have skyrocketed in the UK after the manufacturer of rival drug Mounjaro announced ...

Tennis champion Serena Williams said Thursday that she is taking weight loss medication after struggling to see results from diet and exercise following the birth of her two daughters, Olympia and ...

Although Wegovy (semaglutide) is often used as a weight-loss medicine, it is well-known to be protective for the heart.

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.